Immunohistochemical features of the gastrointestinal tract tumors

Journal of Gastrointestinal Oncology

Volumn 3, Issue 3, 2012, Pages 262-284

  Wong, Hannah H ^a   Chu, Peiguo ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Gastrointestinal neoplasms; Immunohistochemistry

Indexed keywords

ACINAR CELL CARCINOMA; ANUS ADENOCARCINOMA; ANUS CARCINOMA; ANUS SQUAMOUS CELL CARCINOMA; APPENDIX GOBLET CELL CARCINOID; APPENDIX MUCINOUS NEOPLASM; BARRETT ESOPHAGUS; BILE DUCT CARCINOMA; CANCER INCIDENCE; CANCER STAGING; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTRIC EPITHELIAL DYSPLASIA; GASTRIC INTESTINAL METAPLASIA; GASTROINTESTINAL NEUROENDOCRINE TUMOR; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HEPATOBILIARY SYSTEM TUMOR; HEPATOBLASTOMA; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LIVER CELL CARCINOMA; MIXED EXOCRINE ENDOCRINE TUMOR; MUCINOUS CYSTIC NEOPLASM; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATOBLASTOMA; REVIEW; SEROUS CYSTIC NEOPLASM; SMALL INTESTINE ADENOCARCINOMA; SOLID PSEUDOPAPILLARY TUMOR; STOMACH ADENOCARCINOMA; TUMOR BIOPSY; VATER PAPILLA ADENOCARCINOMA; WESTERN HEMISPHERE;

EID: 84995812877     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2012.019     Document Type: Review

References (214)

1. Sasajima K, Takai A, Taniguchi Y, et al. Polypoid squamous cell carcinoma of the esophagus. Cancer 1989;64:94-7.
2. Brown LM, Hoover R, Silverman D, et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 2001;153:114-22.
3. Gunnlaugsson GH, Wychulis AR, Roland C, e al. Analysis of the records of 1,657 patients with carcinoma of the esophagus and cardia of the stomach. Surg Gynecol Obstet 1970;130:997-1005.
4. Sons HU, Borchard F. Esophageal cancer. Autopsy findings in 171 cases. Arch Pathol Lab Med 1984;108:983-8.
5. Chu PG, Lyda MH, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology 2001;39:9-16.
6. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10.
7. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-72.
8. Tsubochi H, Suzuki T, Suzuki S, et al. Immunohistochemical study of basaloid squamous cell carcinoma, adenoid cystic and mucoepidermoid carcinoma in the upper aerodigestive tract. Anticancer Res 2000;20:1205-11.
9. van Dorst EB, van Muijen GN, Litvinov SV, et al. The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells. J Clin Pathol 1998;51:679-84.
10. He D, Zhang DK, Lam KY, et al. Prevalence of HPV infection in esophageal squamous cell carcinoma in Chinese patients and its relationship to the p53 gene mutation. Int J Cancer 1997;72:959-64.
11. Matsha T, Erasmus R, Kafuko AB, et al. Human papillomavirus associated with oesophageal cancer. J Clin Pathol 2002;55:587-90.
12. Sturm I, Petrowsky H, Volz R, et al. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 2001;19:2272-81.
13. Nakamura T, Ide H, Eguchi R, et al. Concomitant analysis of p16/INK4, cyclin D1, and retinoblastoma protein expression in esophageal squamous cell carcinoma. Hepatogastroenterology 2003;50:1321-6.
14. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002;346:836-42.
15. Stein HJ, Siewert JR. Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management. Dysphagia 1993;8:276-88.
16. Dahms BB, Greco MA, Strandjord SE, et al. Barrett's esophagus in three children after antileukemia chemotherapy. Cancer 1987;60:2896-900.
17. Dahms BB, Rothstein FC. Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. Gastroenterology 1984;86:318-23.
18. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
19. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 2002;15:611-6.
20. Shearer C, Going J, Neilson L, et al. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease. Histopathology 2005;47:268-75.
21. Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999;30:288-94.
22. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999;59:1003-7.
23. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999;35:517-24.
24. Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's oesophagus. Histopathology 2000;37:99-107.
25. Kimura H, Konishi K, Kaji M, et al. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report. Hepatogastroenterology 2001;48:1662-4.
26. Glickman JN, Yang A, Shahsafaei A, et al. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 2001;32:1157-65.
27. Fléjou JF, Svrcek M. Barrett's oesophagus--a pathologist's view. Histopathology 2007;50:3-14.
28. Chu PG, Jiang Z, Weiss LM. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol 2003;27:952-9.
29. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol 2006;30:871-7.
30. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993;270:1320.
31. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-56.
32. Hamilton SR, Smith RR, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 1988;19:942-8.
33. Bearzi I, Brancorsini D, Santinelli A, et al. Gastric dysplasia: a ten-year follow-up study. Pathol Res Pract 1994;190:61-8.
34. Di Gregorio C, Morandi P, Fante R, et al. Gastric dysplasia. A follow-up study. Am J Gastroenterol 1993;88:1714-9.
35. Fertitta AM, Comin U, Terruzzi V, et al. Clinical significance of gastric dysplasia: a multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group. Endoscopy 1993;25:265-8.
36. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol 2002;97:2514-23.
37. Shen B, Ormsby AH, Shen C, et al. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction. Cancer 2002;94:820-31.
38. Jovanovic I, Tzardi M, Mouzas IA, et al. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction. Histol Histopathol 2002;17:445-54.
39. Schilling D, Spiethoff A, Rosenbaum A, et al. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients. Pathol Res Pract 2005;200:801-5.
40. Kim HS, Lee JS, Freund JN, et al. CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. J Gastroenterol Hepatol 2006;21:438-42.
41. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27-39.
42. Ramón JM, Serra L, Cerdó C, et al. Dietary factors and gastric cancer risk. A case-control study in Spain. Cancer 1993;71:1731-5.
43. Lambert R, Guilloux A, Oshima A, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002;97:811-8.
44. Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-8.
45. Taniere P, Borghi-Scoazec G, Saurin JC, et al. Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am J Surg Pathol 2002;26:1213-21.
46. Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology 2003;43:127-34.
47. Gulmann C, Counihan I, Grace A, et al. Cytokeratin 7/20 and mucin expression patterns in oesophageal, cardia and distal gastric adenocarcinomas. Histopathology 2003;43:453-61.
48. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 2004;122:61-9.
49. Goldstein NS, Long A, Kuan SF, et al. Colon signet ring cell adenocarcinoma: immunohistochemical characterization and comparison with gastric and typical colon adenocarcinomas. Appl Immunohistochem Mol Morphol 2000;8:183-8.
50. Shibata D, Tokunaga M, Uemura Y, et al. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am J Pathol 1991;139:469-74.
51. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769-74.
52. Dei Tos AP. The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. Virchows Arch 2003;442:421-8.
53. Chu PG, Weiss LM. Modern Immunohistochemistry. c2009. Chapter 6, Tumors of the Digestive System; New York: Cambridge University Press; p188-254.
54. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134-42.
55. Greenson JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 2003;16:366-75.
56. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
57. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.
58. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78.
59. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107-13.
60. Doglioni C, Wotherspoon AC, Moschini A, et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992;339:834-5.
61. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.
62. + follicular lymphomas. Am J Clin Pathol 1999;111:488-94.
63. Streubel B, Huber D, Wöhrer S, et al. Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjögren's syndrome. Clin Cancer Res 2004;10:476-80.
64. Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006;30:1546-53.
65. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
66. Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol 1996;25:722-8.
67. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol 2009;19:58-69.
68. Chen ZM, Ritter JH, Wang HL. Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol 2005;29:890-6.
69. Sessa F, Furlan D, Zampatti C, et al. Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch 2007;451:649-57.
70. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of Gallbladder, extrahepatic bile ducts, and ampulla of Vater. Third Series, Fascicle 27 ed. Washington DC: Armed Force Institute of Pathology; 2000.
71. Williams ED, Sandler M. The classification of carcinoid tum ours. Lancet 1963;1:238-9.
72. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
73. Kimura N, Pilichowska M, Okamoto H, et al. Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors. Mod Pathol 2000;13:140-6.
74. Alumets J, Håkanson R, Ingemansson S, et al. Substance P and 5-HT in granules isolated from an intestinal argentaffin carcinoid. Histochemistry 1977;52:217-22.
75. Alumets J, Alm P, Falkmer S, et al. Immunohistochemical evidence of peptide hormones in endocrine tumors of the rectum. Cancer 1981;48:2409-15.
76. Yang K, Ulich T, Cheng L, et al. The neuroendocrine products of intestinal carcinoids. An immunoperoxidase study of 35 carcinoid tumors stained for serotonin and eight polypeptide hormones. Cancer 1983;51:1918-26.
77. Märtensson H, Nobin A, Sundler F, et al. Endocrine tumors of the ileum. Cytochemical and clinical aspects. Pathol Res Pract 1985;180:356-63.
78. Burke AP, Sobin LH, Federspiel BH, et al. Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases. Arch Pathol Lab Med 1990;114:700-4.
79. Mertz H, Vyberg M, Paulsen SM, et al. Immunohistochemical detection of neuroendocrine markers in tumors of the lungs and gastrointestinal tract. Appl Immunohistochem 1998;6:175-80.
80. Al-Khafaji B, Noffsinger AE, Miller MA, et al. Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors. Hum Pathol 1998;29:992-9.
81. Fahrenkamp AG, Wibbeke C, Winde G, et al. Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract. Virchows Arch 1995;426:361-7.
82. Sobin LH, Hjermstad BM, Sesterhenn IA, et al. Prostatic acid phosphatase activity in carcinoid tumors. Cancer 1986;58:136-8.
83. Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005;123:394-404.
84. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol 2004;28:1169-76.
85. La Rosa S, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch 2004;445:248-54.
86. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-9.
87. Jaffee IM, Rahmani M, Singhal MG, et al. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med 2006;130:1522-6.
88. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
89. Gala M, Chung DC. Hereditary colon cancer syndromes. Semin Oncol 2011;38:490-9.
90. Bussey HJ, Veale AM, Morson BC. Genetics of gastrointestinal polyposis. Gastroenterology 1978;74:1325-30.
91. Croitoru ME, Cleary SP, Di Nicola N, et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 2004;96:1631-4.
92. Jenkins MA, Croitoru ME, Monga N, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 2006;15:312-4.
93. Boparai KS, Mathus-Vliegen EM, Koornstra JJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut 2010;59:1094-100.
94. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-53.
95. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998;5:751-6.
96. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.
97. Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res 1994;14:1635-9.
98. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
99. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10.
100. Raspollini MR, Nesi G, Baroni G, et al. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. Appl Immunohistochem Mol Morphol 2005;13:358-62.
101. Suh N, Yang XJ, Tretiakova MS, et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005;18:1217-22.
102. Nonaka D, Kusamura S, Baratti D, et al. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology 2006;49:381-7.
103. Butler JA, Houshiar A, Lin F, et al. Goblet cell carcinoid of the appendix. Am J Surg 1994;168:685-7.
104. Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol 2008;32:1429-43.
105. Isaacson P. Crypt cell carcinoma of the appendix (so-called adenocarcinoid tumor). Am J Surg Pathol 1981;5:213-24.
106. Gulubova MV, Yovchev Y, Vlaykova T, et al. Application of light microscopical and ultrastructural immunohistochemistry in the study of goblet cell carcinoid in the appendix. World J Surg Oncol 2008;6:15.
107. Hristov AC, Young RH, Vang R, et al. Ovarian metastases of appendiceal tumors with goblet cell carcinoidlike and signet ring cell patterns: a report of 30 cases. Am J Surg Pathol 2007;31:1502-11.
108. Tang LH. Epithelial neoplasms of the appendix. Arch Pathol Lab Med 2010;134:1612-20.
109. Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol 2005;12:291-311.
110. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85-91.
111. Bradley RF, Stewart JH 4th, Russell GB,et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551-9.
112. Panarelli NC, Yantiss RK. Mucinous neoplasms of the appendix and peritoneum. Arch Pathol Lab Med 2011;135:1261-8.
113. Chu PG, Chung L, Weiss LM, et al. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol 2011;35:1830-6.
114. Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am 2004;13:263-75.
115. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008;113:2892-900.
116. Ryan DP, Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol 2000;12:345-52.
117. Beal KP, Wong D, Guillem JG, et al. Primary adenocarcinoma of the anus treated with combined modality therapy. Dis Colon Rectum 2003;46:1320-4.
118. Shia J. An update on tumors of the anal canal. Arch Pathol Lab Med 2010;134:1601-11.
119. Goldblum JR, Hart WR. Perianal Paget's disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol 1998;22:170-9.
120. Hamm H, Vroom TM, Czarnetzki BM. Extramammary Paget's cells: further evidence of sweat gland derivation. J Am Acad Dermatol 1986;15:1275-81.
121. Nowak MA, Guerriere-Kovach P, Pathan A, et al. Perianal Paget's disease: distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein-15 and cytokeratin 20 expression. Arch Pathol Lab Med 1998;122:1077-81.
122. Ito Y, Watanabe S, Usui Y, et al. Expression of cytokeratin antigen 20 in perianal Paget's disease. Br J Dermatol 1999;140:1169-70.
123. Ramalingam P, Hart WR, Goldblum JR. Cytokeratin subset immunostaining in rectal adenocarcinoma and normal anal glands. Arch Pathol Lab Med 2001;125:1074-7.
124. Battles OE, Page DL, Johnson JE. Cytokeratins, CEA, and mucin histochemistry in the diagnosis and characterization of extramammary Paget's disease. Am J Clin Pathol 1997;108:6-12.
125. Cohen C, Guarner J, DeRose PB. Mammary Paget's disease and associated carcinoma. An immunohistochemical study. Arch Pathol Lab Med 1993;117:291-4.
126. Lundquist K, Kohler S, Rouse RV. Intraepidermal cytokeratin 7 expression is not restricted to Paget cells but is also seen in Toker cells and Merkel cells. Am J Surg Pathol 1999;23:212-9.
127. Smith KJ, Tuur S, Corvette D, et al. Cytokeratin 7 staining in mammary and extramammary Paget's disease. Mod Pathol 1997;10:1069-74.
128. Vanstapel MJ, Gatter KC, De Wolf-Peeters C, et al. Immunohistochemical study of mammary and extra-mammary Paget's disease. Histopathology 1984;8:1013-23.
129. Mori O, Hachisuka H, Sasai Y. Immunohistochemical demonstration of epithelial membrane antigen (EMA), carcinoembryonic antigen (CEA), and keratin on mammary and extramammary Paget's disease. Acta Histochem 1989;85:93-100.
130. Filotico R, De Santis M, Filotico M. Morphologic and immunohistochemical observations on the mammary and extramammary Paget's disease: implications for the histogenesis. Pathologica 1992;84:275-85.
131. Brummer O, Stegner HE, Böhmer G, et al. HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol Oncol 2004;95:336-40.
132. Keatings L, Sinclair J, Wright C, et al. c-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study. Histopathology 1990;17:243-7.
133. Kuan SF, Montag AG, Hart J, et al. Differential expression of mucin genes in mammary and extramammary Paget's disease. Am J Surg Pathol 2001;25:1469-77.
134. Ohira S, Itoh K, Osada K, et al. Vulvar Paget's disease with underlying adenocarcinoma simulating breast carcinoma: case report and review of the literature. Int J Gynecol Cancer 2004;14:1012-7.
135. Ganjei P, Giraldo KA, Lampe B, et al. Is immunocytochemistry helpful in assessing the surgical margins? J Reprod Med 1990;35:1002-4.
136. Olson DJ, Fujimura M, Swanson P, et al. Immunohistochemical features of Paget's disease of the vulva with and without adenocarcinoma. Int J Gynecol Pathol 1991;10:285-95.
137. Zhang J, Dhakal I, Yan H, et al. Trends in pancreatic cancer incidence in nine SEER Cancer Registries, 1973- 2002. Ann Oncol 2007;18:1268-79.
138. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998;7:67-91.
139. Hruban RH, Fukushima N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol 2007;20:S61-70.
140. Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol 2001;115:695-702.
141. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002;33:1078-85.
142. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002;21:391-400.
143. Chhieng DC, Benson E, Eltoum I, et al. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer 2003;99:365-71.
144. Hruban RH, Fukushima N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol 2007;20:S61-70.
145. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008;1:306-16.
146. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002;15:1087-95.
147. Levi E, Klimstra DS, Andea A, et al. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004;57:456-62.
148. Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999;23:410-22.
149. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
150. Volkan Adsay N. Cystic lesions of the pancreas. Mod Pathol 2007;20:S71-93.
151. Lüttges J, Feyerabend B, Buchelt T, et al. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 2002;26:466-71.
152. Wilentz RE, Albores-Saavedra J, Hruban RH. Mucinous cystic neoplasms of the pancreas. Semin Diagn Pathol 2000;17:31-42.
153. He H, Luthringer DJ, Hui P, et al. Expression of CD56 and WT1 in ovarian stroma and ovarian stromal tumors. Am J Surg Pathol 2008;32:884-90.
154. Handra-Luca A, Fléjou JF, Rufat P, et al. Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology 2006;48:813-21.
155. Adsay NV, Conlon KC, Zee SY, et al. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer 2002;94:62-77.
156. Murakami Y, Uemura K, Ohge H, et al. Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery 2006;140:448-53.
157. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an " intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004;28:839-48.
158. Ueda M, Miura Y, Kunihiro O, et al. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology 2005;52:398-403.
159. Klimstra DS. Nonductal neoplasms of the pancreas. Mod Pathol 2007;20:S94-112.
160. Buetow PC, Buck JL, Pantongrag-Brown L, et al. Solid and papillary epithelial neoplasm of the pancreas: imaging-pathologic correlation on 56 cases. Radiology 1996;199:707-11.
161. Bardales RH, Centeno B, Mallery JS, et al. Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of solid-pseudopapillary tumor of the pancreas: a rare neoplasm of elusive origin but characteristic cytomorphologic features. Am J Clin Pathol 2004;121:654-62.
162. Kosmahl M, Seada LS, Jänig U, et al. Solid-pseudopapillary tumor of the pancreas: its origin revisited. Virchows Arch 2000;436:473-80.
163. Notohara K, Hamazaki S, Tsukayama C, et al. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol 2000;24:1361-71.
164. Tiemann K, Kosmahl M, Ohlendorf J, et al. Solid pseudopapillary neoplasms of the pancreas are associated with FLI-1 expression, but not with EWS/FLI-1 translocation. Mod Pathol 2006;19:1409-13.
165. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002;160:1361-9.
166. Tang WW, Stelter AA, French S, et al. Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas. Mod Pathol 2007;20:509-13.
167. Campbell F, Azadeh B. Cystic neoplasms of the exocrine pancreas. Histopathology 2008;52:539-51.
168. Compton CC. Serous cystic tumors of the pancreas. Semin Diagn Pathol 2000;17:43-55.
169. Kosmahl M, Wagner J, Peters K, et al. Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol 2004;28:339-46.
170. Lam KY, Lo CY. Pancreatic endocrine tumour: a 22- year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997;23:36-42.
171. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol 2012;24:46-55.
172. Lloyd RV, Mervak T, Schmidt K, et al. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol 1984;8:607-14.
173. Portela-Gomes GM, Hacker GW, Weitgasser R. Neuroendocrine cell markers for pancreatic islets and tumors. Appl Immunohistochem Mol Morphol 2004;12:183-92.
174. Kamisawa T, Tu Y, Egawa N, et al. Ductal and acinar differentiation in pancreatic endocrine tumors. Dig Dis Sci 2002;47:2254-61.
175. Yantiss RK, Chang HK, Farraye FA, et al. Prevalence and prognostic significance of acinar cell differentiation in pancreatic endocrine tumors. Am J Surg Pathol 2002;26:893-901.
176. Klimstra DS, Wenig BM, Adair CF, et al. Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol 1995;19:1371-89.
177. Drut R, Jones MC. Congenital pancreatoblastoma in Beckwith-Wiedemann syndrome: an emerging association. Pediatr Pathol 1988;8:331-9.
178. Nishimata S, Kato K, Tanaka M, et al. Expression pattern of keratin subclasses in pancreatoblastoma with special emphasis on squamoid corpuscles. Pathol Int 2005;55:297- 302.
179. Tanaka Y, Kato K, Notohara K, et al. Significance of aberrant (cytoplasmic/nuclear) expression of beta-catenin in pancreatoblastoma. J Pathol 2003;199:185-90.
180. Klimstra DS, Wenig BM, Adair CF, et al. Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol 1995;19:1371-89.
181. Morohoshi T, Kanda M, Horie A, et al. Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma, and solid cystic (papillary-cystic) tumor. Cancer 1987;59:739-47.
182. Hoorens A, Lemoine NR, McLellan E, et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 1993;143:685-98.
183. Abraham SC, Wu TT, Hruban RH, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 2002;160:953-62.
184. Ballas KD, Rafailidis SF, Demertzidis C, et al. Mixed exocrine-endocrine tumor of the pancreas. JOP 2005;6:449-54.
185. Klimstra DS, Rosai J, Heffess CS. Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol 1994;18:765-78.
186. Klöppel G. Mixed exocrine-endocrine tumors of the pancreas. Semin Diagn Pathol 2000;17:104-8.
187. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
188. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
189. Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol 2004;11:239-49.
190. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006;14:266-72.
191. White GR, Kelsey AM, Varley JM, et al. Somatic glypican 3 (GPC3) mutations in Wilms' tumour. Br J Cancer 2002;86:1920-2.
192. Ohmori S, Shiraki K, Sugimoto K, et al. Expression of CD34-positive sinusoidal endothelial cells in patients with HBV-associated chronic liver diseases. Int J Mol Med 2004;14:179-84.
193. Scott FR, el-Refaie A, More L, et al. Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma. Histopathology 1996;28:472-4.
194. Ruck P, Xiao JC, Kaiserling E. Immunoreactivity of sinusoids in hepatocellular carcinoma. An immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34. Arch Pathol Lab Med 1995;119:173-8.
195. Maeda T, Adachi E, Kajiyama K, et al. CD34 expression in endothelial cells of small hepatocellular carcinoma: its correlation with tumour progression and angiographic findings. J Gastroenterol Hepatol 1995;10:650-4.
196. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal " capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 1998;22:656-62.
197. Christensen WN, Boitnott JK, Kuhajda FP. Immunoperoxidase staining as a diagnostic aid for hepatocellular carcinoma. Mod Pathol 1989;2:8-12.
198. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000;113:374-82.
199. Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002;26:978-88.
200. Christensen WN, Boitnott JK, Kuhajda FP. Immunoperoxidase staining as a diagnostic aid for hepatocellular carcinoma. Mod Pathol 1989;2:8-12.
201. Johnson DE, Herndier BG, Medeiros LJ, et al. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 1988;12:187-97.
202. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25.
203. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000;88:2471-7.
204. Boberg KM, Bergquist A, Mitchell S,et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-11.
205. Goodman ZD. Neoplasms of the liver. Mod Pathol 2007;20:S49-60.
206. Rullier A, Le Bail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 2000;24:870-6.
207. Reynolds P, Urayama KY, Von Behren J, et al. Birth characteristics and hepatoblastoma risk in young children. Cancer 2004;100:1070-6.
208. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983;14:512-37.
209. Rowland JM. Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol 2002;39:478-83.
210. Fasano M, Theise ND, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Mod Pathol 1998;11:934-8.
211. Redston MS, Wanless IR. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. Mod Pathol 1996;9:233-7.
212. Bhathal PS, Hughes NR, Goodman ZD. The so-called bile duct adenoma is a peribiliary gland hamartoma. Am J Surg Pathol 1996;20:858-64.
213. Chu PG, Schwarz RE, Lau SK, et al. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 2005;29:359-67.
214. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 2005;29:381-9.